Published in Mol Ther on February 27, 2014
Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells. Leukemia (2015) 0.81
From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells. Hum Gene Ther (2014) 0.79
GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. Oncoimmunology (2016) 0.77
Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy. Mol Ther (2015) 0.76
A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. Breast Cancer (Auckl) (2015) 0.75
Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy. Cancers (Basel) (2017) 0.75
Adoptive T-Cell Therapy for Solid Tumors. Am Soc Clin Oncol Educ Book (2017) 0.75
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A (1992) 6.61
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest (2008) 6.15
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A (1993) 5.23
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol (2006) 5.02
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 3.82
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature (2005) 3.70
CARs on track in the clinic. Mol Ther (2011) 2.86
Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res (1990) 2.56
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood (2010) 2.52
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol (2009) 2.43
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A (1999) 2.22
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood (2013) 2.13
Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol (2005) 2.08
The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol (2005) 1.89
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res (2011) 1.82
Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A (1991) 1.78
The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res (1975) 1.72
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A (2009) 1.71
Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest (2004) 1.70
Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood (2011) 1.69
Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials. Leuk Lymphoma (2012) 1.57
HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res (2004) 1.49
Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood (2004) 1.43
Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res (2010) 1.41
Cytotoxic T lymphocyte hybridomas that mediate specific tumor-cell lysis in vitro. Proc Natl Acad Sci U S A (1981) 1.36
Targeting stroma to treat cancers. Semin Cancer Biol (2011) 1.33
Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest (1998) 1.30
TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 1.08
Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res (2010) 1.04
Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J Immunol (2001) 1.03
Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther (2010) 1.03
T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology (2012) 1.03
The adaptive immune response to sporadic cancer. Immunol Rev (2007) 1.02
Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother (1998) 1.02
Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res (2003) 1.01
Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol (1993) 1.00
Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood (2009) 0.99
Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci U S A (1994) 0.99
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother (2012) 0.98
Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology (2012) 0.94
Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. J Immunol (1997) 0.90
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol (2013) 0.86
Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future. Immunotherapy (2009) 0.78